Early statin use and the progression of Alzheimer disease: A total population-based case-control study

Medicine (United States)

Volumn 94, Issue 47, 2015, Pages e2143-

  Lin, Feng Cheng ^a,b   Chuang, Yun Shiuan ^a   Hsieh, Hui Min ^a   Lee, Tzu Chi ^c   Chiu, Kuei Fen ^a,c   Liu, Ching Kuan ^a   Wu, Ming Tsang ^a,d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Pingtung Hospital   (Taiwan)

^c NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ATORVASTATIN; BENZODIAZEPINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; DRUG USE; EARLY INTERVENTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; NEUROPROTECTION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; TAIWANESE; CASE CONTROL STUDY; DAILY LIFE ACTIVITY; DYSLIPIDEMIAS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TAIWAN;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; CHOLINESTERASE INHIBITORS; COMORBIDITY; DISEASE PROGRESSION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TAIWAN;

EID: 84983514598     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002143     Document Type: Article

References (37)

1. Ageing and life course. World Health Organization. http:// www.who.int/ageing/about/facts/en/.
2. Brookmeyer R, Corrada MM, Curriero FC, et al. Survival following a diagnosis of Alzheimer disease. Arch Neurol. 2002;59:1764-1767.
3. De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci. 2000;113:1857-1870.
4. Shobab LA, Hsiung GY, Feldman HH. Cholesterol in Alzheimer's disease. Lancet Neurol. 2005;4:841-852.
5. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70:1795-1802.
6. Kandiah N, Feldman HH. Therapeutic potential of statins in Alzheimer's disease. J Neurol Sci. 2009;283:230-234.
7. National Health Insurance Research Database. http://nhird.nhri.org.tw/en/index.htm.
8. Wu IC, Lin MY, Yu FJ, et al. A short-term effect of low-dose aspirin on major hemorrhagic risks in primary prevention: a casecrossover design. PLoS One. 2014;9:e98326.
9. Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst. 2010;102:179-186.
10. US Centers for Diseases Control and Prevention A, Georgia. International Classification of diseases, Ninth Revision (ICD-9). http://www.cdc.gov/nchs/icd/icd9.htm 2014.
11. Chang YP, Chiu GF, Kuo FC, et al. Eradication of helicobacter pylori is associated with the progression of dementia: a population-based study. Gastroenterol Res Pract. 2013:Article ID 175729, 5 pages.
12. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf. 2005;14:465-476.
13. Patorno E, Glynn RJ, Hernandez-Diaz S, et al. Studies with many covariates and few outcomes: selecting covariates and implementing propensity-score-based confounding adjustments. Epidemiology. 2014;25:268-278.
14. Wahrle S, Das P, Nyborg AC, et al. Cholesterol-dependent gammasecretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis. 2002;9:11-23.
15. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004;5:347-360.
16. Whitfield JF. Can statins put the brakes on Alzheimer's disease? Expert Opin Investig Drugs. 2006;15:1479-1485.
17. Kaesemeyer WH, Caldwell RB, Huang J, et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 1999;33:234-241.
18. Pac-Soo C, Lloyd DG, Vizcaychipi MP, et al. Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration. J Alzheimers Dis. 2011;27:1-10.
19. Wang Q, Yan J, Chen X, et al. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol. 2011;230:27-34.
20. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in communitydwelling elderly people. Arch Neurol. 2002;59:223-227.
21. Li G, Shofer JB, Rhew IC, et al. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc. 2010;58:1311-1317.
22. Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;23:2010;74:956-964.
23. Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77:556-563.
24. Steenland K, Zhao L, Goldstein FC, et al. Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment. J Am Geriatr Soc. 2013;61: 1449-1455.
25. Riekse RG, Li G, Petrie EC, et al. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis. 2006;10:399-406.
26. Vuletic S, Riekse RG, Marcovina SM, et al. Statins of different brain penetrability differentially affect CSF PLTP activity. Dement Geriatr Cogn Disord. 2006;22:392-398.
27. Haag MD, Hofman A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80: 13-17.
28. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol. 2011;68:1385-1392.
29. Bettermann K, Arnold AM, Williamson J, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis. 2012;21:436-444.
30. Wu CK, Yang YH, Lin TT, et al. Statin use reduces the risk of dementia in elderly patients: a nationwide data survey and propensity analysis. J Intern Med. 2015;277:343-352.
31. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol. 2011;68:1239-1244.
32. Alves TC, Rays J, Fraguas R Jr et al. Localized cerebral blood flow reductions in patients with heart failure: a study using 99mTc-HMPAO SPECT. J Neuroimaging. 2005;15:150-156.
33. Ruitenberg A, den Heijer T, Bakker SL, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam study. Ann Neurol. 2005;57:789-794.
34. Kopf D, Frolich L. Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. J Alzheimers Dis. 2009;16:677-685.
35. Kuljis RO, Salkovic-Petrisic M. Dementia, diabetes, Alzheimer's disease, and insulin resistance in the brain: progress, dilemmas, new opportunities, and a hypothesis to tackle intersecting epidemics. J Alzheimers Dis. 2011;25:29-41.
36. Rusanen M, Kivipelto M, Levalahti E, et al. Heart diseases and long-term risk of dementia and Alzheimer's disease: a populationbased CAIDE study. J Alzheimers Dis. 2014.
37. Parmar MK, Carpenter J, Sydes MR. More multiarm randomised trials of superiority are needed. Lancet. 2014;384:283-284.